ePrints

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I

Lookup NU author(s): Professor Heinz Grunze

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background: Eslicarbazepine acetate (ESL) is an anticonvulsant approved as an adjunctive therapy in adults with partial onset seizures.Objective: To evaluate the efficacy, safety and tolerability of ESL in the treatment of acute mania and prevention of recurrence in bipolar disorder I.Methods: Two 3-week multicentre, double-blind, randomised, placebo-controlled studies in acute mania (study BIA-2093-203: dose titrated by response, ESL 600-1800 mg or 800-2400 mg, once-daily; study BIA-2093-204: fixed doses of 600, 1200 and 1800 mg, once-daily) were followed by a recurrence prevention study consisting of a 2-week open-label period (900 mg, once-daily) continued by a double-blind, parallel-group, fixed dose (300, 900 and 1800 mg, once-daily) period for a minimum of 6 months. The primary end point was changed from baseline until the end of the 3-week treatment period in Young Mania Rating Scale (YMRS) in studies BIA-2093-203 and BIA-2093-204, and the proportion of patients showing no worsening according to the Clinical Global Impressions - Bipolar Version (CGI-BP) over Part II in study BIA-2093-205.Results.: In study BIA-2093-203 (n=160, ITT), neither dose group was statistically different from placebo in the primary endpoint, though the ESL 800-2400 mg showed a greater reduction in YMRS score (p=0.0523). CGI-BP score changes for mania and overall bipolar illness indicate a significant improvement in patient symptomatology for the ESL 800-2400 mg group (from preceding and worst phase) and for ESL 600-1800 mg group (from worst phase only) when compared to placebo. Study BIA-2093-204 (n=38) results were inconclusive due to premature termination caused by recruitment difficulties. In study BIA-2093-205 (n=85, ITT), at least 50% of patients showed no worsening in all treatment groups (p=0.250). ESL adverse events were mostly of mild and moderate intensities and consistent with previously reported observations for ESL.Conclusion: ESL treatment was not significantly different from placebo in manic patients in the primary outcome, but secondary outcomes may be suggestive of efficacy. The recurrence prevention study provides preliminary support for efficacy of ESL in patients recovered from an acute manic episode. (C) 2014 Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Grunze H, Kotlik E, Costa R, Nunes T, Falcao A, Almeida L, Soares-Da-Silva P

Publication type: Article

Publication status: Published

Journal: Journal of Affective Disorders

Year: 2015

Volume: 174

Pages: 70-82

Print publication date: 15/03/2015

Online publication date: 18/11/2014

Acceptance date: 10/11/2014

ISSN (print): 0165-0327

ISSN (electronic): 1573-2517

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.jad.2014.11.013

DOI: 10.1016/j.jad.2014.11.013

Altmetrics

Share